Piccolo Francesco, Pitman Nicholas, Bhatnagar Rahul, Popowicz Natalia, Smith Nicola A, Brockway Ben, Nickels Robert, Burke Andrew J, Wong Conroy A, McCartney Ruth, Choo-Kang Brian, Blyth Kevin G, Maskell Nick A, Lee Y C Gary
1 Department of Medicine, Swan District Hospital, Perth, Australia.
Ann Am Thorac Soc. 2014 Nov;11(9):1419-25. doi: 10.1513/AnnalsATS.201407-329OC.
Intrapleural tissue plasminogen activator (tPA)/deoxyribonuclease (DNase) therapy for pleural infection given at the time of diagnosis has been shown to significantly improve radiological outcomes. Published cases are limited to only a single randomized controlled trial and a few case reports.
Multinational observation series to evaluate the pragmatic "real-life" application of tPA/DNase treatment for pleural infection in a large cohort of unselected patients.
All patients from eight centers who received intrapleural tPA/DNase for pleural infection between January 2010 and September 2013 were included. Measured outcomes included treatment success at 30 days, volume of pleural fluid drained, improvement in radiographic pleural opacity and inflammatory markers, need for surgery, and adverse events.
Of 107 patients treated, the majority (92.3%) were successfully managed without the need for surgical intervention. No patients died as a result of pleural infection. Most patients (84%) received tPA/DNase more than 24 hours after failing to respond to initial conservative management with antibiotics and thoracostomy. tPA/DNase increased fluid drained from a median of 250 ml (interquartile range [IQR], 100-654) in the 24 hours preceding commencement of intrapleural therapy to 2,475 ml (IQR 1,800-3,585) in the 72 hours following treatment initiation (P < 0.05). We observed a corresponding clearance of pleural opacity on chest radiographs from a median of 35% (IQR 25-31) to 14% (7-28) of the hemithorax (P < 0.001), as well as significant reduction in C-reactive protein (P < 0.05). Pain necessitating escalation of analgesia occurred in 19.6% patients, and nonfatal bleeding occurred in 1.8%.
This large series of patients who received intrapleural tPA/DNase therapy provides important evidence that the treatment is effective and safe, especially as a "rescue therapy" in patients who do not initially respond to antibiotics and thoracostomy drainage.
诊断时给予胸膜腔内组织型纤溶酶原激活剂(tPA)/脱氧核糖核酸酶(DNase)治疗胸膜感染已被证明能显著改善影像学结果。已发表的病例仅限于一项随机对照试验和少数病例报告。
进行多中心观察系列研究,以评估tPA/DNase治疗胸膜感染在一大群未经选择的患者中的实际“现实生活”应用情况。
纳入2010年1月至2013年9月期间在八个中心接受胸膜腔内tPA/DNase治疗胸膜感染的所有患者。测量的结果包括30天时的治疗成功率、胸腔引流液量、胸部X线片上胸膜混浊度和炎症标志物的改善情况、手术需求以及不良事件。
在接受治疗的107例患者中,大多数(92.3%)成功接受治疗,无需手术干预。没有患者因胸膜感染死亡。大多数患者(84%)在对初始抗生素和胸腔造口术保守治疗无反应超过24小时后接受tPA/DNase治疗。tPA/DNase使胸腔内治疗开始前24小时引流液的中位数从250毫升(四分位间距[IQR],100 - 654)增加到治疗开始后72小时的2475毫升(IQR 1800 - 3585)(P < 0.05)。我们观察到胸部X线片上胸膜混浊度相应清除,从半侧胸腔的中位数35%(IQR 25 - 31)降至14%(7 - 28)(P < 0.001),同时C反应蛋白也显著降低(P < 0.05)。19.6%的患者出现需要加强镇痛的疼痛,1.8%的患者发生非致命性出血。
这一大系列接受胸膜腔内tPA/DNase治疗的患者提供了重要证据,表明该治疗有效且安全,特别是作为对初始抗生素和胸腔造口引流无反应患者的“挽救疗法”。